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Alcohol consumption at moderate levels has been associated with decreased risk of coronary heart
disease (CHD). However, the cardio-protective effect of alcohol may be restricted to subjects with a
particular genotype of the cholesteryl ester transfer protein (CETP) polymorphism. There is evidence for
this from one study in men, but the ﬁnding has not been conﬁrmed since. The present study speciﬁcally
re-examines the potential modiﬁcation of the association between alcohol consumption and CHD by the
CETP TaqIB (rs708272) polymorphism in a sample including both men and women. The INTERGENE case-
control study consists of 618 patients with CHD and 2921 control subjects, of whom 19% were homo-
zygous for the CETP TaqIB B2 allele. Alcohol consumption was categorized into sex-speciﬁc tertiles of
ethanol intake, with non-drinkers constituting a separate category. Logistic regression was used to
determine the association between CHD with genotype, ethanol intake, and their interaction. Partici-
pants with intermediate ethanol intake (2nd tertile) had lower risk of CHD than those with low ethanol
intake (odds ratio [OR] ¼ 0.65; 95% conﬁdence interval [CI] 0.50e0.85). The strongest protective asso-
ciation was seen in the CETP TaqIB B2 homozygotes for intermediate vs. low ethanol intake (odds ratio
OR ¼ 0.21; 95% CI 0.10e0.44). The interaction between ethanol intake and genotype was statistically
signiﬁcant (p ¼ 0.008), and of similar size in men and women though signiﬁcant only in men (p ¼ 0.01).
The effect modiﬁcation could not be explained by differences in lifestyle, socioeconomics, or alcohol-
related biological variables such as HDLecholesterol. Our study is the ﬁrst to replicate previous ﬁnd-
ings of an effect modiﬁcation in men. It gives only suggestive results for women, possibly due to the small
number of female cases (n ¼ 165). The prevented fraction for the favorable combination of genotype and
alcohol consumption is about 6%, a value suggesting that the cardio-protective effect of moderate alcohol
consumption applies only to a small segment of the general population.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Alcohol consumption at a so-called “moderate” level, up to 1
drink/day for women and 2 for men (1 drink corresponding to 14 g
or 0.6 ounces of ethanol), has been associated with a decreased risk
of coronary heart disease (CHD) (Doll, Peto, Boreham, & Sutherland,
2005; Mäkelä, Valkonen, & Poikolainen, 1997; Mukamal & Rimm,
2001; O’Keefe, Bybee, & Lavie, 2007; U.S. Dept. of Agriculture andinterest.
th and Community Medicine,
54, SE e 405 30 Gothenburg,
.
Inc. This is an open access article uU.S. Dept. of Health and Human Services, 2005). The consistency
of the association suggests that there might be a causal relationship,
and a number of pathways including antioxidant effects of poly-
phenols in wine (Opie & Lecour, 2007), and the more general high
density lipoprotein-cholesterol (HDL) raising effect of alcohol per se
have been suggested (Lewis, 2006). The latter would be via the role
of HDL in the reverse transport of cholesterol from peripheral ar-
teries to the liver, which has a CHD risk-reducing effect and is partly
regulated by the glycoprotein cholesteryl ester transfer protein
(CETP). The activity is determined by the CETP gene, including the
intronic TaqIB polymorphism (rs708272). In 1995, Fumeron et al.
showed an interaction between the CETP TaqIB polymorphism and
alcohol consumption on the risk for coronary heart disease in ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Northern Ireland and France (Fumeron et al., 1995). In B2 homozy-
gotes, the odds ratio for myocardial infarction was reduced by
ethanol intake of 50 g/day or more compared to lower or no intake
(OR¼ 0.39; 95% CI 0.20e0.75), while a similar protective association
was not observed for B1 carriers (p value for interaction ¼ 0.034).
Later studies on this topic gave conﬂicting results (Boekholdt et al.,
2005; Corella et al., 2010; Jensen, Mukamal, Overvad, & Rimm, 2008)
and none fully replicated the original result.
Varying effects of the CETP TaqIB polymorphism may be due to
heterogenous populations and different impact of lifestyle habits,
but the possibility that the cardio-protective effect of alcohol is
restricted to a subset of the population with a certain CETP TaqIB
genotype cannot be excluded. We therefore aimed to re-examine
the association between alcohol consumption and coronary heart
disease and its possible modiﬁcation by the CETP TaqIB poly-
morphism in a population-based case-control study based in
southwest Sweden. In contrast to many previous studies, we are
able to use several ethanol exposure categories and study possible
non-linear associations with CHD.
Materials and methods
Study population
The study is a population-based case-control study that is part of
the INTERGENE research program assessing the INTERplay between
GENEtic susceptibility, lifestyle, biological, and psychosocial factors
for the risk of chronic diseases in southwest Sweden. The INTER-
GENE cohort comprises randomly sampled individuals from a
source population aged 25e74 at the time of sampling on April 1,
2001. As of December 2004, 3614 members of the target population
sample had been examined. In addition to the cohort, the study
population includes surviving cases of acute coronary heart disease
identiﬁed from the same source population as the cohort.
Case registration and deﬁnition
Inparallelwith thecohortexaminations, patientsbelowtheageof
75 years admitted to 3 regional hospitals for acute coronary syn-
drome and diagnosed with myocardial infarction (ICD 10:
I21.0eI21.9), with typical history, ECG, and enzyme changes or un-
stable angina (ICD 10: I20.0) were invited to the study while still in
the ward. Six hundred eighteen patients (453 men and 165 women)
were included in this study, of whom 209men and 86 women had a
ﬁrst-time acute myocardial infarction or unstable angina while the
remaining323hadanexacerbationofpreviouslydiagnosedcoronary
heart disease. All the registered cases underwent similar procedures
as the cohort members. For further information on the study popu-
lation, recruitment, and participation see www.intergene.gu.se and
previous publications (Berg et al., 2008; Strandhagen et al., 2010).
Study procedures
The examination included self-administered questionnaires on
environmental and lifestyle-related exposure variables, anthropo-
metric measures, and collection of venous blood samples. During
examination, all participants were asked about the frequency of
intake of different types of alcoholic beverage (low-alcohol beer,
medium-strong beer, strong beer, wine, dessert wine, and spirits).
Control subjects were asked about the previous 12 months before
examination, and cases were asked about the previous 12 months
before their most recent coronary event. For each type of alcohol,
there were 8 response categories, ranging from never to 3 or more
times per day. These self-reported frequencies of intake werecombined with age and sex-dependent standard servings of alco-
holic beverage consumed per occasion to calculate the total con-
sumption of ethanol in g/day (Berg et al., 2009). In addition, the
following health, lifestyle, and socioeconomic variables were
recorded and analyzed as dichotomous factors: diabetes status, use
of lipid-lowering drugs, smoking status (ever vs. never), leisure
time physical activity (at least 4 h/week vs. less), level of education
(university vs. less), being married or living with a partner (yes vs.
no), and having ﬁnancial difﬁculties (yes vs. no).
Laboratory analysis
Participants fasted at least 4 h before blood samples were drawn.
For the coronary patients, blood samples were drawn after the
event. The blood samples were collected into tubes containing 0.1%
EDTA for immediate serum lipid and glucose analysis. Serum total
cholesterol and triglyceride concentrations were determined using
enzymatic assays. Serum HDL-cholesterol concentrations were
measured after dextran sulfate magnesium precipitation of apoB-
containing lipoproteins. Whole blood was stored at 70 C in
1.5 mL aliquots for DNA extraction.
Genotyping
The TaqIB polymorphism (rs708272) is located in theﬁrst intron of
the CETP gene. The genotyping was performed using the 7900HT
sequence detection system and the genotyping assay C_9615318_10
(AppliedBiosystems,FosterCity,CA).Eachreactionconsistedof1.25mL
of 20XC_9615318_10 genotyping assaymix,12.5 mLTaqManUniversal
PCR Master Mix, 10.25 mL RNase-free water, and 1 mL of sample DNA
(10e15 ng). The PCR reactionwas initially heated for 10 min at 95 C,
followed by 40 cycles of 15 s at 92 C and 1 min at 60 C.
Statistical methods
Differences in means of continuous variables or proportions
were tested using t test (for age) or age-adjusted linear and logistic
regression, stratiﬁed by sex. The values of BMI, triglycerides, HDL-
cholesterol, and ethanol intake (current abstainers excluded)
were log-transformed before analysis. Multiple logistic regression
was used to describe the association between explanatory variables
such as genotype and ethanol intake and their interaction with
CHD. All models were adjusted for age, BMI, HDL-cholesterol
(including quadratic terms), sex, and smoking status. Three cate-
gories of ethanol intake were deﬁned using sex-speciﬁc cut-off
values for tertiles of ethanol intake in the male and the female
cohort, while the group of non-users of alcohol deﬁned a 4th group.
Because abstainers constitute a heterogenous group ranging from
former alcohol abuse to life-long abstention, the tertile of con-
sumers with lowest alcohol consumptionwas chosen as a reference
category. The results are given in terms of odds-ratios (OR) and
their 95% conﬁdence intervals in parentheses. The analysis was
repeated for ﬁrst-time patients (n ¼ 295) only, excluding patients
with a history of cardiovascular disease. We also retested the as-
sociation between ethanol, genotype, and CHD based on tertiles of
ethanol intake per kg body weight as an alternative way to adjust
for the confounding effect of body weight. In a post hoc analysis, we
tested for differences in leisure time physical activity (at least 4 h/
week vs. less), education (university vs. less), being married or
living with a partner (yes vs. no), ﬁnancial insecurity (yes vs. no), as
well as diabetes status (yes vs. no) and triglyceride level between
the 2 genotype groups B2B2 vs. not B2B2 using the age-adjusted
regression methods. The statistical analyses were performed us-
ing SAS version 9.3 (SAS Institute Inc., Cary, NC, USA.). Statistical
signiﬁcance was set at p value 0.05 (2 sided test).
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The prevented fraction of a disease related to a particular indicator
ofprotection is the fractionof cases in thepopulation that isprevented
by themarker of protection and/or factors associatedwith it. This is a
theoretical conceptwhichcanbebasedonrelative riskorodds ratioas
an approximation of the former (Miettinen, 1974). The theoretical
prevented fraction (PF) of CHD cases in the general population avoi-
ded by the favorable factor (here, a speciﬁc combination of genotype
and ethanol intake) is calculated as PF ¼ P  (1  OR) where the
prevalence of the factor (P) is estimated in the cohort subjects and OR
denotes the odds ratio for CHD in subjects with the favorable factor
compared to those without (Gargiullo, Rothenberg, & Wilson, 1995).
Ethics statement
All subjects gave their written consent to the study, and the
protocol was approved by the Regional ethics review board, For-
skningsetikkommité (no. Ö 237/2000). The study complies with the
Declaration of Helsinki.
Results
Description of CHD cases and controls
Descriptive properties of CHD cases and control subjects are
shown in Table 1. A lower percentage of alcohol users and a
lower median level of consumption among users were seen in
coronary patients of both sexes. The distribution of ethanol
intake among users was strongly skewed to the right, with a
larger variation of intake among the cases compared with the
controls. The age-adjusted difference by case status was also
observed with respect to ethanol intake per kg body weight. Due
to the lower alcohol consumption in women (cases and/or con-
trols) compared to men, this variable was categorized using sex-
speciﬁc percentiles derived from the cohort, to allow for an
analysis combining both sexes. Among current consumers, cut-
off values for tertiles of ethanol intake are given by 3.2 and 6.3
for women, and 6.5 and 13.1 for men (in g/day). As described in
the Materials and methods section, the intakes among casesTable 1
Properties of patients and controls from the INTERGENE case-control study, stratiﬁed by
categorical variables, p value for age-adjusted test for comparison by case status.
Women
Cases
n ¼ 165
Users of alcohol 132 (80%)
Ethanol intake (g/day)a,b 3.3 (1.6e7.4)*
Ethanol intake/body weight (g/day/kg)a,b 0.04 (0.03e0.09)**
CETP genotype: B1B1 58 (35.2%)
B1B2 84 (50.9%)
B2B2 23 (13.9%)
Age (years) 62.7 (8.1)*
Body mass index (kg/m2)a 28.2 (4.8)**
HDL-cholesterol (mmol/L)a 1.56 (0.43)***
Triglycerides (mmol/L)a 1.65 (1.13)
Ever smoking 100 (61%)***
History of diabetes 30 (18.2%)***
Cholesterol lowering drugs 117 (70.8%)***
Leisure time physical activity (4 h/week) 132 (80%)***
Higher education 140 (85%)*
Being married/cohabitate 107 (65%)
Financial insecurity 39 (24%)**
p values: *<0.05, **<0.01, ***<0.001.
a Log-transformed before analysis.
b Alcohol consumers only, median (1st quartile e 3rd quartile).refer to 1 year before the event, and in controls to 1 year before
examination.
The distribution of genotype was similar in both female and
male cases and controls, and did not deviate fromHardyeWeinberg
equilibrium. The prevalence of the B2 allele in the cohort did not
depend on age (data not shown).
At the time of the examination, male and female CHD cases
were on average 10 and 12 years older than the respective control
subjects and had a higher age-adjusted BMI. CHD cases had lower
levels of HDL-cholesterol, whereas triglyceride levels were higher
in male patients compared to controls. The proportion of ever-
smoking, self-reported diabetes and use of cholesterol-lowering
drugs was higher among coronary patients for both sexes. Pa-
tients were also less likely to report leisure time physical activity.
Higher education was related with case status in women, while
living alone was associated with CHD in men. Patients of both
sexes reported ﬁnancial difﬁculties more often than controls.
Risk for CHD by CETP TaqIB polymorphism
The B2B2 genotype was associated with a lower CHD risk,
adjusted for age, sex, body mass index (BMI), and smoking status
[OR ¼ 0.71 (0.53e0.94)], with a similar magnitude in men [OR ¼
0.74 (0.53e1.05)] and women [OR ¼ 0.62 (0.37e1.07)]. The effect of
B2B2 relative to B1B1 was no longer observed when further
adjusted for HDL-cholesterol (Table 2A). Since there was no risk
difference between B1B2 and B1B1 genotypes, we restricted sub-
sequent analyses to the comparison between B2 homozygotes and
B1B2 combined with B1B1.
Risk for CHD by alcohol consumption and modiﬁcation of risk by
CETP TaqIB polymorphism
Table 2B shows the odds ratio for CHD by category of ethanol
intake, adjusted for age, sex, smoking status, BMI, and HDL-
cholesterol. The group with intermediate ethanol intake had a
lower risk compared to low intake, while there was no association
with CHD for abstainers and high consumers.
Table 2C shows the results of the joint model of CHD for ethanol
intake and genotype including their interaction, presented in termssex. Mean value (SD) for continuous variables (except ethanol intake), counts (%) for
Men
Controls Cases Controls
n ¼ 1543 n ¼ 453 n ¼ 1378
1346 (87%) 402 (89%) 1283 (93%)
4.7 (2.7e7.7) 9.0 (4.3e16.4)* 9.7 (5.6e15.6)
0.07 (0.04e0.11) 0.10 (0.05e0.20)* 0.12 (0.07e0.19)
517 (33.5%) 151 (33.3%) 421 (30.5%)
730 (47.3%) 229 (50.6%) 690 (50.1%)
296 (19.2%) 73 (16.1%) 267 (19.4%)
50.5 (13.6) 61.4 (8.4)*** 51.1 (13.4)
25.5 (4.3) 27.7 (4.0)*** 26.6 (3.6)
1.78 (0.45) 1.28 (0.34)*** 1.46 (0.38)
1.21 (0.67) 1.71 (1.30)*** 1.57 (1.09)
756 (49%) 352 (78%)*** 705 (51%)
40 (2.6%) 78 (17.2%)*** 61 (4.4%)
81 (5.3%) 357 (78.8%)*** 94 (6.8%)
1411 (92%) 382 (84%)*** 1211 (88%)
1004 (65%) 366 (81%) 999 (73%)
1120 (73%) 329 (73%)*** 1078 (79%)
316 (21%) 82 (18%)** 226 (17%)
Table 2
Odds ratio of CHD (95% CI) for CETP TaqIB genotype and ethanol intake. Separatemodels for genotype (A) and ethanol intake (B), respectively, and the results from a joint model
of genotype, ethanol intake, and their interaction (C), all regressions adjusted for age, sex, smoking status, BMI, and HDL-cholesterol.
A: Main effect of genotype
B1B1 B1B2 B2B2
1(ref) 1.03 (0.83e1.29) 0.89 (0.66e1.20)
B: Main effect of ethanol intakea
Abstainer Low Intermediate High
1.06 (0.76e1.47) 1 (ref) 0.65 (0.50e0.85)** 0.90 (0.70e1.17)
C: Joint effect of genotype and ethanol intakea
Abstainer Low Intermediate High
B1B1 þ B1B2b 1.12 (0.77e1.62) 1 (ref) 0.80 (0.59e1.06) 1.03 (0.77e1.36)
B2B2b 0.76 (0.36e1.64) 1 (ref) 0.21 (0.10e0.44)*** 0.48 (0.26e0.88)*
Interactionc 0.68 (0.29e1.59) 1 (ref) 0.27 (0.12e0.59)** 0.46 (0.24e0.91)*
p values: *<0.05, **<0.01, ***<0.001.
a Low: \ < 3.2, _ < 6.5, intermediate: \ 3.2e6.3, _ 6.5e13.1, high: \ > 6.3, _ > 13.1 (g/day).
b OR for ethanol intake (ref ¼ low intake) by genotype category.
c OR for the product term ethanol intake  genotype.
Fig. 1. Odds ratio and 95% CI for CHD by categories of ethanol intake and CETP TaqIB
genotype. OR for CHD by categories of ethanol intake for all genotypes combined (A)
and stratiﬁed by genotype (B, C), including the interaction between ethanol intake and
genotype. Both models are adjusted for age, sex, smoking, BMI, and HDL. The lower
part of each panel gives the number of cases/the total number of subjects in each
category of ethanol intake.
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by genotype category (line 1 & 2). Again, the group with interme-
diate ethanol intake had the lowest risk compared to low intake,
but this wasmarkedlymore pronounced in B2 homozygotes than in
B1 carriers. A negative association with risk of CHD was also
observed for high vs. low intake in B2 homozygotes, but not in B1
carriers or in the full sample. The last row of Table 2C shows a
signiﬁcant effect modiﬁcation of intermediate or high ethanol
intake by CETP B2B2 genotype, compared to low intake. The overall
p value for interaction was equal to 0.008. The OR for CHD in ab-
stainers did not differ signiﬁcantly from the risk in subjects with
low ethanol intake in either stratum, and the effect modiﬁcation
was not changed when current abstainers were chosen as refer-
ence. The cardio-protection at intermediate ethanol intake was also
observed in men and women separately [OR ¼ 0.42 (0.20e0.88) for
B2B2 vs. non B2B2 in men with intermediate intake, and OR ¼ 0.34
(0.08e1.52) for women with intermediate intake]. However, this
was signiﬁcant in men only (overall p value for interaction ¼ 0.01
for men, 0.2 for women). The corresponding OR for both sexes
combined was OR ¼ 0.41 (0.22e0.79).
Fig. 1 summarizes the results of the separate model for ethanol
intake (1A) and the joint model for ethanol intake, CETP B2B2 ge-
notype, and their interaction (1B & 1C). The inverse association of
intermediate ethanol intake with risk of CHD observed in the full
sample is mainly due to a strong effect in the B2 homozygotes,
which constitute 19% of the sample. Only in the latter category is it
observed that high ethanol intake has a smaller risk than low
ethanol intake.
Sensitivity analyses
A similar U shaped risk curve among B2 homozygotes was
observed when alcohol consumption was categorized into quartiles
(and abstainers) or when alcohol consumptionwas based on tertiles
of ethanol intake per kg body weight (data not shown). The results
given in Table 2 did not depend on the adjustment for HDL-
cholesterol, nor did they change when an interaction between ge-
notype and HDL-cholesterol was included (p value for
interaction>0.1, datanot shown). Therewerenodifferences between
the 2 genotype strata regarding leisure time physical activity, educa-
tion, being married or living with a partner, ﬁnancial insecurity, tri-
glyceride level, or diabetes status, and the inclusion of these variables
in themodeldidnot reduce theeffectmodiﬁcation reported inTable2.
The protective effect of B2B2 genotype in the categories of in-
termediate or high ethanol intake was more pronounced when werestricted the cases to the 295 ﬁrst-time coronary cases who would
be less likely to have altered their alcohol intake due to previous
events: OR ¼ 0.13 (0.04e0.41) for intermediate vs. low intake in
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OR¼ 0.70 (0.48e1.03) for intermediate vs. low intake in B1 carriers,
OR¼ 1.06 (0.75e1.52) for high vs. low intake in B1 carriers, overall p
value for interaction ¼ 0.015. Also, we observed the same interac-
tion pattern as described in Table 2 when age was restricted to 60
years or above (373 cases, 856 controls, average age ¼ 67 in both
groups). In this subsample, the odds ratio of CHD for intermediate
vs. low ethanol intake was given by OR ¼ 0.16 (0.04, 0.62) in B2
homozygotes compared to OR ¼ 0.78 (0.53, 1.15) in B1 allele car-
riers, p value for interaction ¼ 0.03.
The cardio-protective effect of alcohol and CETP TaqIB polymorphism
as a prevented fraction
In order to place this apparent gene-environment interaction in
a public health context, we estimated the fraction of coronary cases
in the population that may have been prevented by intermediate or
high alcohol consumption among the B2B2 carriers. First, we
calculated the prevalence (P) of the combination of B2 homozy-
gosity and intermediate or high ethanol intake, which was given by
0.125 in the cohort-based control subjects. This, together with the
odds ratio for CHD [OR ¼ 0.49 (95% CI 0.35e0.68) yielded a PF of
0.06 (0.04e0.09)], indicates that the frequency of CHD disease
would have been increased by roughly 6% if this combination of
alcohol consumption and B2B2 genotype had not existed in the
population. The implications of this relatively low estimate of
prevented cases are discussed in more detail below.
Discussion
In this population-based study, the overall observation of a
reduced risk for CHD in subjects with intermediate or high alcohol
consumption (3.2 g/day for women and 6.5 g/day for men) was
most strongly observed in CETP TaqIB B2 homozygotes. This
modiﬁcation of the effect of ethanol intake by genotype was of
similar size in both men and women in spite of their different level
of alcohol consumption. However, the effect modiﬁcation was sta-
tistically signiﬁcant in men only, the result in women probably
being limited by sample size because only 27% of 618 CHD cases
were female. The cardio-protective effect of alcohol in the CETP
TaqIB B2 homozygotes could not be explained by a mediating effect
of HDL-cholesterol or an interaction between HDL-cholesterol and
genotype, nor was the effect reduced after adjustment for different
socioeconomic and lifestyle variables, or explained by selective
survival of certain genotype groups. The ﬁnding that the protective
effect of alcohol is not due to HDL-cholesterol is consistent with the
results in a recent Norwegian study (Magnus et al., 2011). Our re-
sults that the reduced risk is associated with intermediate and high
consumption in a certain CETP genotype strengthens the notion
that there is a direct effect of alcohol intake on the risk of CHD and is
not due to confounding factors or clustering of healthy habits.
These results conﬁrm the ﬁrst report on the association between
CETP genotype, alcohol, and CHD, a case-control study onmyocardial
infarction comprising men in Northern Ireland and 3 areas in France
(ECTIM) (Corbex et al., 2000; Fumeron et al., 1995). This 1995 study
showed decreasing CHD risk with increasing ethanol intake in B2
homozygotes compared to the other genotypes, which was observed
for an ethanol intake larger or equal to 50 g/day and was strongest
among the heavy drinkers (75 g per day). Our study is the ﬁrst to
replicate this interaction effect in men; however, there was a much
lower level of alcohol intake and a U shaped risk proﬁle with respect
to ethanol intake. Our result for women is also similar to results from
the Nurses’ Health Study, where a 60% risk reduction was found for
female B2 carriers consuming at least 5 g/day compared to none, and
no effect of alcohol in B1 homozygotes (Jensen et al., 2008), but theinteraction was not signiﬁcant either. Lack of an interaction effect in
both the female and the corresponding male cohort studied by
Jensen et al. (2008) could be explained by the smaller sample size
and the comparison between B2 carriers and B1 homozygotes.
Finally, our results canbecontrasted to ameta-analysis of 7 studies
including ECTIM (Fumeron et al., 1995) that found no signiﬁcant
interaction betweenCETP TaqIB and ethanol onCHD (Boekholdt et al.,
2005). The lackof a convincingeffectmaybeexplainedby the fact that
adichotomizedalcohol variablehad tobeused comparing currentuse
of alcohol to abstinencewhen summarizing the results of the studies.
The division into drinking/no drinking is obviously too crude to
identify the non-linear association between ethanol intake and CHD.
Thiscouldalsobetheexplanation for theadverseassociationbetween
CETP TaqIB B2B2 genotype and CHD in drinkers reported in a more
recent study from Spain (Corella et al., 2010).
A strength of this study is that we use several levels of ethanol
intake in addition to abstinence even though the exposure is based
on self-reported usual alcohol consumption, which is prone to many
types of error. Under-reporting of alcohol consumption is a known
problem, and might explain part of the discrepancy with other
studies regarding the absolute amount of alcohol intake. However,
the positive correlation between HDL-cholesterol and ethanol intake
in a previous study of the cohort (Tognon et al., 2012) supports the
validity of the latter. Among patients, there could be under-reporting
due to knowledge of disease or truly reduced alcohol consumption
after the event; however, coronary patients in Sweden are not usu-
ally advised to change their alcohol consumption. The main result of
this study, the protective effect of intermediate alcohol consumption
in B2 homozygotes compared to non-B2B2 carriers (Fig. 1), is robust
in the sense that misclassiﬁcation of ethanol intake should be in-
dependent of genotype. Still we cannot exclude the possibility that
the subgroup of intermediate (‘moderate’) users of alcohol displays a
clustering of generally healthier lifestyle variables, which act
together in the protection against CHD.When retested adding leisure
time physical activity, ﬁnancial security, educational level, marital
status, and diabetes status as covariates, no change in the effect of
alcohol consumption and genotype on CHD was observed, nor did
we see differences in these variables comparing the favorable com-
bination of intermediate or high ethanol intake and B2B2 genotype
with the rest of the study population.
The cardio-protective effect of alcohol e not for everyone?
The common attitude today is that moderate alcohol intake will
decrease everyone’s risk of coronary heart disease. Together with
the ECTIM study (Fumeron et al., 1995), the present study suggests
that this message may be too general and should be assessed in
light of the weak overall effect of alcohol on CHD in the general
population and the emerging knowledge about genetic suscepti-
bility. Future research should re-assess the magnitude of the pre-
vented fraction in the general population, using data on past and
current alcohol consumption and incident cases of CHD.
Acknowledgments
The study was funded by the Swedish Research Council [VR 521-
2010-2984], the Swedish Heart-Lung Foundation [2009-0390], and
the Swedish council for working life and social research [Epilife
2006-1506].
References
Berg, C., Lappas, G., Wolk, A., Strandhagen, E., Torén, K., Rosengren, A., et al. (2009).
Eating patterns and portion size associated with obesity in a Swedish popula-
tion. Appetite, 52, 21e26.
K. Mehlig et al. / Alcohol 48 (2014) 695e700700Berg, C. M., Lappas, G., Strandhagen, E., Wolk, A., Torén, K., Rosengren, A., et al.
(2008). Food patterns and cardiovascular disease risk factors: the Swedish
INTERGENE research program. The American Journal of Clinical Nutrition, 88,
289e297.
Boekholdt, S. M., Sacks, F. M., Jukema, J. W., Shepherd, J., Freeman, D. J.,
McMahon, A. D., et al. (2005). Cholesteryl ester transfer protein TaqIB variant,
high-density lipoprotein cholesterol levels, cardiovascular risk, and efﬁcacy of
pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Circulation, 111, 278e287.
Corbex, M., Poirier, O., Fumeron, F., Betoulle, D., Evans, A., Ruidavets, J. B., et al.
(2000). Extensive association analysis between the CETP gene and coronary
heart disease phenotypes reveals several putative functional polymorphisms
and gene-environment interaction. Genetic Epidemiology, 19, 64e80.
Corella, D., Carrasco, P., Amiano, P., Arriola, L., Chirlaque, M. D., Huerta, J. M., et al.
(2010). Common cholesteryl ester transfer protein gene variation related to
high-density lipoprotein cholesterol is not associated with decreased coronary
heart disease risk after a 10-year follow-up in a Mediterranean cohort: modu-
lation by alcohol consumption. Atherosclerosis, 211, 531e538.
Doll, R., Peto, R., Boreham, J., & Sutherland, L. (2005). Mortality in relation to alcohol
consumption: a prospective study among male British doctors. International
Journal of Epidemiology, 34, 199e204.
Fumeron, F., Betoulle, D., Luc, G., Behague, I., Ricard, S., Poirier, O., et al. (1995).
Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester
transfer protein gene on plasma high density lipoprotein and the risk of
myocardial infarction. The Journal of Clinical Investigation, 96, 1664e1671.
Gargiullo, P. M., Rothenberg, R. B., & Wilson, H. G. (1995). Conﬁdence intervals,
hypothesis tests, and sample sizes for the prevented fraction in cross-sectional
studies. Statistics in Medicine, 14, 51e72.
Jensen, M. K., Mukamal, K. J., Overvad, K., & Rimm, E. B. (2008). Alcohol
consumption, TaqIB polymorphism of cholesteryl ester transfer protein,high-density lipoprotein cholesterol, and risk of coronary heart disease in men
and women. European Heart Journal, 29, 104e112.
Lewis, G. F. (2006). Determinants of plasma HDL concentrations and reverse
cholesterol transport. Current Opinion in Cardiology, 21, 345e352.
Magnus, P., Bakke, E., Hoff, D. A., Høiseth, G., Graff-Iversen, S., Knudsen, G. P., et al.
(2011). Controlling for high-density lipoprotein cholesterol does not affect the
magnitude of the relationship between alcohol and coronary heart disease.
Circulation, 124, 2296e2302.
Mäkelä, P., Valkonen, T., & Poikolainen, K. (1997). Estimated numbers of deaths from
coronary heart disease “caused” and “prevented” by alcohol: an example from
Finland. Journal of Studies on Alcohol, 58, 455e463.
Miettinen, O. S. (1974). Proportion of disease caused or prevented by a given
exposure, trait or intervention. American Journal of Epidemiology, 99, 325e332.
Mukamal, K. J., & Rimm, E. B. (2001). Alcohol’s effects on the risk for coronary heart
disease. Alcohol Research & Health, 25, 255e261.
O’Keefe, J. H., Bybee, K. A., & Lavie, C. J. (2007). Alcohol and cardiovascular health:
the razor-sharp double-edged sword. Journal of the American College of Cardi-
ology, 50, 1009e1014.
Opie, L. H., & Lecour, S. (2007). The red wine hypothesis: from concepts to protective
signalling molecules. European Heart Journal, 28, 1683e1693.
Strandhagen, E., Berg, C., Lissner, L., Nunez, L., Rosengren, A., Torén, K., et al. (2010).
Selection bias in a population survey with registry linkage: potential effect on
socioeconomic gradient in cardiovascular risk. European Journal of Epidemiology,
25, 163e172.
Tognon, G., Berg, C., Mehlig, K., Thelle, D., Strandhagen, E., Gustavsson, J., et al.
(2012). Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total
cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake.
PLoS One, 7, e40878.
U.S. Dept. of Agriculture and U.S. Dept. of Health and Human Services. (2005).
Nutrition and Your Health: Dietary Guidelines for Americans.
